BRIEF—Teva wins FDA nod and launches generic Saxenda, first generic GLP-1

The US subsidiary of Israeli generics giant Teva Pharmaceuticals today announced US Food and Drug Administration (FDA) approval and US launch of a generic version of Saxenda (liraglutide injection).

“With this approval, and by launching a generic for Saxenda (liraglutide injection), we will provide patients in the US the first ever generic GLP-1 product specifically indicated for weight loss,” said Ernie Richardsen, SVP, head of US Commercial Generics at Teva.

“This is the fifth first-to-market entry of a Teva generic this year and is an important addition to Teva's diverse complex generics portfolio, demonstrating once again our proven ability to sustain a world class Generics Powerhouse,” he added.